查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
HIV 治療藥物市場：按藥物類別和配銷通路分類：2023-2032 年全球機會分析和產業預測
市場調查報告書
商品編碼
1414722

HIV 治療藥物市場：按藥物類別和配銷通路分類：2023-2032 年全球機會分析和產業預測

HIV Drugs Market By Medication Class, By Distribution Channel : Global Opportunity Analysis and Industry Forecast, 2023-2032
出版日期: | 出版商: Allied Market Research | 英文 35 Pages | 商品交期: 2-3個工作天內

價格

2022 年，HIV 治療市場價值為 328 億美元，預計 2023 年至 2032 年複合年成長率為 4.5%，到 2032 年將達到 511 億美元。

人類免疫力缺乏病毒（HIV）是一種攻擊人體免疫系統的感染疾病。它會削弱身體並使其更容易患各種疾病。抗逆轉錄病毒藥物（HIV藥物）如核苷逆轉錄酶抑制劑（NRTI）、蛋白酶抑制劑（PI）、進入抑制劑和HIV整合酶鏈轉移抑制劑用於治療HIV。

HIV藥物市場-IMG1

該報告可以客製化（需要單獨的費用和時間表）。

  • 市場策略
  • 按產品/細分市場區隔
  • 新產品開發/主要企業產品矩陣
  • 根據客戶興趣新增其他公司簡介
  • 平均售價分析/價位分析
  • 品牌佔有率分析
  • 十字交叉細分市場分析—市場規模與預測
  • 歷史市場資料
  • 主要參與者的詳細資料（Excel格式，包括位置、聯絡資訊、供應商/供應商網路等）
  • SWOT分析

目錄

第1章簡介

第 2 章執行摘要

第3章市場概況

  • 市場定義和範圍
  • 主要發現
    • 影響因素
    • 主要投資機會
  • 波特五力分析
  • 市場動態
    • 促進因素
      • 愛滋病毒感染者人數增加
      • 各政府機構努力提高人們對愛滋病毒/愛滋病診斷和管理的認知
      • HIV治療學名藥簡介
    • 抑制因素
      • HIV療法的核准和商業化的嚴格監管要求
    • 機會
      • 研發線產品增加

第 4 章 HIV 藥物市場：依藥物類別

  • 概述
  • 按藥物類別分類的伴隨藥物
    • 按藥物類別和品牌分類的愛滋病毒組合藥物藥物市場
  • 核苷逆轉錄酶抑制劑（NRTI）
    • 按品牌分類的核苷逆轉錄酶抑制劑 (NRTI) HIV 治療市場
  • 非核苷類逆轉錄酶抑制劑（NNRTI）
    • 按品牌分類的非核苷逆轉錄酶抑制劑 (NNRTI) HIV 治療市場
  • 蛋白酶抑制劑 (PI)
    • 按品牌分類的蛋白酶抑制劑 (PI) HIV 治療市場
  • 進入抑制劑
    • 按進入抑制劑品牌分類的 HIV 治療市場
  • HIV整合酶鏈轉移抑制劑
    • HIV整合酶鏈轉移抑制劑HIV治療藥物市場（按品牌）
  • 其他

第5章 HIV 治療藥物市場：按配銷通路

  • 概述
  • 醫院藥房
  • 藥局和零售藥局
  • 網路藥房

第6章 HIV 治療藥物市場：按地區

  • 概述
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙
    • 其他
  • 亞太地區
    • 日本
    • 中國
    • 澳洲
    • 印度
    • 韓國
    • 其他
  • 拉丁美洲/中東/非洲
    • 巴西
    • 沙烏地阿拉伯
    • 南非
    • 其他

第7章 競爭形勢

  • 介紹
  • 關鍵成功策略
  • 10家主要企業產品圖譜
  • 競爭對手儀表板
  • 競爭熱圖
  • 2022年主要企業定位

第8章 公司簡介

  • AbbVie Inc.
  • Merck & Co., Inc.
  • Boehringer Ingelheim International GmbH
  • Gilead Sciences, Inc.
  • GlaxoSmithKline plc
  • Johnson & Johnson
  • F. Hoffmann-La Roche Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Cipla Ltd.
  • Bristol-Myers Squibb Company
Product Code: A01537

According to a new report published by Allied Market Research, titled, "HIV Drugs Market," The hiv drugs market was valued at $32.8 billion in 2022, and is estimated to reach $51.1 billion by 2032, growing at a CAGR of 4.5% from 2023 to 2032. Human immunodeficiency virus (HIV) is a type of infection that attacks the immune system of the body. It weakens the body and makes it easier to get sick with any diseases. The antiretroviral drugs (HIV drugs) such as nucleoside reverse transcriptase inhibitors (NRTIs), protease inhibitors (PIs), entry inhibitors, HIV integrase strand transfer inhibitors and others are used for the treatment of HIV.

HIV Drugs Market - IMG1

Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)

  • Go To Market Strategy
  • Market share analysis of players by products/segments
  • New Product Development/ Product Matrix of Key Players
  • Additional company profiles with specific to client's interest
  • Average Selling Price Analysis / Price Point Analysis
  • Brands Share Analysis
  • Criss-cross segment analysis- market size and forecast
  • Historic market data
  • Key player details (including location, contact details, supplier/vendor network etc. in excel format)
  • SWOT Analysis

Key Market Segments

By Medication Class

  • Multi-Class Combination Drugs
    • Brand
    • Atripla
    • Complera
    • Prezcobix
    • Stribild
    • Genvoya
    • Odefsey
    • Symtuza
    • Triumeq
    • Descovy
    • Dovato
    • Others
  • Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
    • Brand
    • Emtriva
    • Epivir
    • Epzicom/Kivexa
    • Truvada
    • Biktarvy
    • Others
  • Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
    • Brand
    • Edurant
    • Others
  • Protease Inhibitors (PIs)
    • Brand
    • Aptivus
    • Kaletra
    • Lexiva/ Telzir
    • Norvir
    • Viracept
    • Others
  • Entry Inhibitors
    • Brand
    • Selzentry
    • Fuzeon
    • Rukobia
  • HIV Integrase Strand Transfer Inhibitors
    • Brand
    • Isentress/Isentress HD
    • Tivicay
    • Apretude
    • Juluca
  • Others

By Distribution Channel

  • Hospital Pharmacies
  • Drugs stores and retail pharmacies
  • Online pharmacies

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • Australia
    • India
    • South Korea
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Saudi Arabia
    • South Africa
    • Rest of LAMEA

Key Market Players:

    • Merck & Co., Inc.
    • Cipla Ltd.
    • F. Hoffmann-La Roche Ltd.
    • Bristol-Myers Squibb Company
    • Gilead Sciences, Inc.
    • AbbVie Inc.
    • Boehringer Ingelheim International GmbH
    • Teva Pharmaceutical Industries Ltd.
    • GlaxoSmithKline plc
    • Johnson & Johnson

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

  • 1.1. Report description
  • 1.2. Key market segments
  • 1.3. Key benefits to the stakeholders
  • 1.4. Research methodology
    • 1.4.1. Primary research
    • 1.4.2. Secondary research
    • 1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

  • 2.1. CXO Perspective

CHAPTER 3: MARKET OVERVIEW

  • 3.1. Market definition and scope
  • 3.2. Key findings
    • 3.2.1. Top impacting factors
    • 3.2.2. Top investment pockets
  • 3.3. Porter's five forces analysis
    • 3.3.1. Low bargaining power of suppliers
    • 3.3.2. Low threat of new entrants
    • 3.3.3. Low threat of substitutes
    • 3.3.4. Low intensity of rivalry
    • 3.3.5. Low bargaining power of buyers
  • 3.4. Market dynamics
    • 3.4.1. Drivers
      • 3.4.1.1. Rise in cases of HIV
      • 3.4.1.2. Initiatives taken by various government associations to raise awareness about diagnosis and management of HIV/AIDS
      • 3.4.1.3. Introduction of generic drugs for HIV
    • 3.4.2. Restraints
      • 3.4.2.1. Stringent regulatory requirements for the approval and commercialization of HIV drugs
    • 3.4.3. Opportunities
      • 3.4.3.1. Increasing number of products in the pipeline

CHAPTER 4: HIV DRUGS MARKET, BY MEDICATION CLASS

  • 4.1. Overview
    • 4.1.1. Market size and forecast
  • 4.2. Multi-Class Combination Drugs
    • 4.2.1. Key market trends, growth factors and opportunities
    • 4.2.2. Market size and forecast, by region
    • 4.2.3. Market share analysis by country
    • 4.2.4. Multi-Class Combination Drugs HIV Drugs Market by Brand
  • 4.3. Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
    • 4.3.1. Key market trends, growth factors and opportunities
    • 4.3.2. Market size and forecast, by region
    • 4.3.3. Market share analysis by country
    • 4.3.4. Nucleoside Reverse Transcriptase Inhibitors (NRTIs) HIV Drugs Market by Brand
  • 4.4. Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
    • 4.4.1. Key market trends, growth factors and opportunities
    • 4.4.2. Market size and forecast, by region
    • 4.4.3. Market share analysis by country
    • 4.4.4. Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) HIV Drugs Market by Brand
  • 4.5. Protease Inhibitors (PIs)
    • 4.5.1. Key market trends, growth factors and opportunities
    • 4.5.2. Market size and forecast, by region
    • 4.5.3. Market share analysis by country
    • 4.5.4. Protease Inhibitors (PIs) HIV Drugs Market by Brand
  • 4.6. Entry Inhibitors
    • 4.6.1. Key market trends, growth factors and opportunities
    • 4.6.2. Market size and forecast, by region
    • 4.6.3. Market share analysis by country
    • 4.6.4. Entry Inhibitors HIV Drugs Market by Brand
  • 4.7. HIV Integrase Strand Transfer Inhibitors
    • 4.7.1. Key market trends, growth factors and opportunities
    • 4.7.2. Market size and forecast, by region
    • 4.7.3. Market share analysis by country
    • 4.7.4. HIV Integrase Strand Transfer Inhibitors HIV Drugs Market by Brand
  • 4.8. Others
    • 4.8.1. Key market trends, growth factors and opportunities
    • 4.8.2. Market size and forecast, by region
    • 4.8.3. Market share analysis by country

CHAPTER 5: HIV DRUGS MARKET, BY DISTRIBUTION CHANNEL

  • 5.1. Overview
    • 5.1.1. Market size and forecast
  • 5.2. Hospital Pharmacies
    • 5.2.1. Key market trends, growth factors and opportunities
    • 5.2.2. Market size and forecast, by region
    • 5.2.3. Market share analysis by country
  • 5.3. Drugs stores and retail pharmacies
    • 5.3.1. Key market trends, growth factors and opportunities
    • 5.3.2. Market size and forecast, by region
    • 5.3.3. Market share analysis by country
  • 5.4. Online pharmacies
    • 5.4.1. Key market trends, growth factors and opportunities
    • 5.4.2. Market size and forecast, by region
    • 5.4.3. Market share analysis by country

CHAPTER 6: HIV DRUGS MARKET, BY REGION

  • 6.1. Overview
    • 6.1.1. Market size and forecast By Region
  • 6.2. North America
    • 6.2.1. Key market trends, growth factors and opportunities
    • 6.2.2. Market size and forecast, by Medication Class
    • 6.2.3. Market size and forecast, by Distribution Channel
    • 6.2.4. Market size and forecast, by country
      • 6.2.4.1. U.S.
      • 6.2.4.1.1. Market size and forecast, by Medication Class
      • 6.2.4.1.2. Market size and forecast, by Distribution Channel
      • 6.2.4.2. Canada
      • 6.2.4.2.1. Market size and forecast, by Medication Class
      • 6.2.4.2.2. Market size and forecast, by Distribution Channel
      • 6.2.4.3. Mexico
      • 6.2.4.3.1. Market size and forecast, by Medication Class
      • 6.2.4.3.2. Market size and forecast, by Distribution Channel
  • 6.3. Europe
    • 6.3.1. Key market trends, growth factors and opportunities
    • 6.3.2. Market size and forecast, by Medication Class
    • 6.3.3. Market size and forecast, by Distribution Channel
    • 6.3.4. Market size and forecast, by country
      • 6.3.4.1. Germany
      • 6.3.4.1.1. Market size and forecast, by Medication Class
      • 6.3.4.1.2. Market size and forecast, by Distribution Channel
      • 6.3.4.2. France
      • 6.3.4.2.1. Market size and forecast, by Medication Class
      • 6.3.4.2.2. Market size and forecast, by Distribution Channel
      • 6.3.4.3. UK
      • 6.3.4.3.1. Market size and forecast, by Medication Class
      • 6.3.4.3.2. Market size and forecast, by Distribution Channel
      • 6.3.4.4. Italy
      • 6.3.4.4.1. Market size and forecast, by Medication Class
      • 6.3.4.4.2. Market size and forecast, by Distribution Channel
      • 6.3.4.5. Spain
      • 6.3.4.5.1. Market size and forecast, by Medication Class
      • 6.3.4.5.2. Market size and forecast, by Distribution Channel
      • 6.3.4.6. Rest of Europe
      • 6.3.4.6.1. Market size and forecast, by Medication Class
      • 6.3.4.6.2. Market size and forecast, by Distribution Channel
  • 6.4. Asia-Pacific
    • 6.4.1. Key market trends, growth factors and opportunities
    • 6.4.2. Market size and forecast, by Medication Class
    • 6.4.3. Market size and forecast, by Distribution Channel
    • 6.4.4. Market size and forecast, by country
      • 6.4.4.1. Japan
      • 6.4.4.1.1. Market size and forecast, by Medication Class
      • 6.4.4.1.2. Market size and forecast, by Distribution Channel
      • 6.4.4.2. China
      • 6.4.4.2.1. Market size and forecast, by Medication Class
      • 6.4.4.2.2. Market size and forecast, by Distribution Channel
      • 6.4.4.3. Australia
      • 6.4.4.3.1. Market size and forecast, by Medication Class
      • 6.4.4.3.2. Market size and forecast, by Distribution Channel
      • 6.4.4.4. India
      • 6.4.4.4.1. Market size and forecast, by Medication Class
      • 6.4.4.4.2. Market size and forecast, by Distribution Channel
      • 6.4.4.5. South Korea
      • 6.4.4.5.1. Market size and forecast, by Medication Class
      • 6.4.4.5.2. Market size and forecast, by Distribution Channel
      • 6.4.4.6. Rest of Asia-Pacific
      • 6.4.4.6.1. Market size and forecast, by Medication Class
      • 6.4.4.6.2. Market size and forecast, by Distribution Channel
  • 6.5. LAMEA
    • 6.5.1. Key market trends, growth factors and opportunities
    • 6.5.2. Market size and forecast, by Medication Class
    • 6.5.3. Market size and forecast, by Distribution Channel
    • 6.5.4. Market size and forecast, by country
      • 6.5.4.1. Brazil
      • 6.5.4.1.1. Market size and forecast, by Medication Class
      • 6.5.4.1.2. Market size and forecast, by Distribution Channel
      • 6.5.4.2. Saudi Arabia
      • 6.5.4.2.1. Market size and forecast, by Medication Class
      • 6.5.4.2.2. Market size and forecast, by Distribution Channel
      • 6.5.4.3. South Africa
      • 6.5.4.3.1. Market size and forecast, by Medication Class
      • 6.5.4.3.2. Market size and forecast, by Distribution Channel
      • 6.5.4.4. Rest of LAMEA
      • 6.5.4.4.1. Market size and forecast, by Medication Class
      • 6.5.4.4.2. Market size and forecast, by Distribution Channel

CHAPTER 7: COMPETITIVE LANDSCAPE

  • 7.1. Introduction
  • 7.2. Top winning strategies
  • 7.3. Product mapping of top 10 player
  • 7.4. Competitive dashboard
  • 7.5. Competitive heatmap
  • 7.6. Top player positioning, 2022

CHAPTER 8: COMPANY PROFILES

  • 8.1. AbbVie Inc.
    • 8.1.1. Company overview
    • 8.1.2. Key executives
    • 8.1.3. Company snapshot
    • 8.1.4. Operating business segments
    • 8.1.5. Product portfolio
    • 8.1.6. Business performance
  • 8.2. Merck & Co., Inc.
    • 8.2.1. Company overview
    • 8.2.2. Key executives
    • 8.2.3. Company snapshot
    • 8.2.4. Operating business segments
    • 8.2.5. Product portfolio
    • 8.2.6. Business performance
    • 8.2.7. Key strategic moves and developments
  • 8.3. Boehringer Ingelheim International GmbH
    • 8.3.1. Company overview
    • 8.3.2. Key executives
    • 8.3.3. Company snapshot
    • 8.3.4. Operating business segments
    • 8.3.5. Product portfolio
    • 8.3.6. Business performance
  • 8.4. Gilead Sciences, Inc.
    • 8.4.1. Company overview
    • 8.4.2. Key executives
    • 8.4.3. Company snapshot
    • 8.4.4. Operating business segments
    • 8.4.5. Product portfolio
    • 8.4.6. Business performance
    • 8.4.7. Key strategic moves and developments
  • 8.5. GlaxoSmithKline plc
    • 8.5.1. Company overview
    • 8.5.2. Key executives
    • 8.5.3. Company snapshot
    • 8.5.4. Operating business segments
    • 8.5.5. Product portfolio
    • 8.5.6. Business performance
    • 8.5.7. Key strategic moves and developments
  • 8.6. Johnson & Johnson
    • 8.6.1. Company overview
    • 8.6.2. Key executives
    • 8.6.3. Company snapshot
    • 8.6.4. Operating business segments
    • 8.6.5. Product portfolio
    • 8.6.6. Business performance
    • 8.6.7. Key strategic moves and developments
  • 8.7. F. Hoffmann-La Roche Ltd.
    • 8.7.1. Company overview
    • 8.7.2. Key executives
    • 8.7.3. Company snapshot
    • 8.7.4. Operating business segments
    • 8.7.5. Product portfolio
    • 8.7.6. Business performance
  • 8.8. Teva Pharmaceutical Industries Ltd.
    • 8.8.1. Company overview
    • 8.8.2. Key executives
    • 8.8.3. Company snapshot
    • 8.8.4. Operating business segments
    • 8.8.5. Product portfolio
    • 8.8.6. Business performance
  • 8.9. Cipla Ltd.
    • 8.9.1. Company overview
    • 8.9.2. Key executives
    • 8.9.3. Company snapshot
    • 8.9.4. Operating business segments
    • 8.9.5. Product portfolio
    • 8.9.6. Business performance
  • 8.10. Bristol-Myers Squibb Company
    • 8.10.1. Company overview
    • 8.10.2. Key executives
    • 8.10.3. Company snapshot
    • 8.10.4. Operating business segments
    • 8.10.5. Product portfolio
    • 8.10.6. Business performance

LIST OF TABLES

  • TABLE 01. GLOBAL HIV DRUGS MARKET, BY MEDICATION CLASS, 2022-2032 ($MILLION)
  • TABLE 02. HIV DRUGS MARKET FOR MULTI-CLASS COMBINATION DRUGS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 03. GLOBAL MULTI-CLASS COMBINATION DRUGS HIV DRUGS MARKET, BY BRAND, 2022-2032 ($MILLION)
  • TABLE 04. HIV DRUGS MARKET FOR NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS (NRTIS), BY REGION, 2022-2032 ($MILLION)
  • TABLE 05. GLOBAL NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS (NRTIS) HIV DRUGS MARKET, BY BRAND, 2022-2032 ($MILLION)
  • TABLE 06. HIV DRUGS MARKET FOR NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS (NNRTIS), BY REGION, 2022-2032 ($MILLION)
  • TABLE 07. GLOBAL NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS (NNRTIS) HIV DRUGS MARKET, BY BRAND, 2022-2032 ($MILLION)
  • TABLE 08. HIV DRUGS MARKET FOR PROTEASE INHIBITORS (PIS), BY REGION, 2022-2032 ($MILLION)
  • TABLE 09. GLOBAL PROTEASE INHIBITORS (PIS) HIV DRUGS MARKET, BY BRAND, 2022-2032 ($MILLION)
  • TABLE 10. HIV DRUGS MARKET FOR ENTRY INHIBITORS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 11. GLOBAL ENTRY INHIBITORS HIV DRUGS MARKET, BY BRAND, 2022-2032 ($MILLION)
  • TABLE 12. HIV DRUGS MARKET FOR HIV INTEGRASE STRAND TRANSFER INHIBITORS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 13. GLOBAL HIV INTEGRASE STRAND TRANSFER INHIBITORS HIV DRUGS MARKET, BY BRAND, 2022-2032 ($MILLION)
  • TABLE 14. HIV DRUGS MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 15. GLOBAL HIV DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 16. HIV DRUGS MARKET FOR HOSPITAL PHARMACIES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 17. HIV DRUGS MARKET FOR DRUGS STORES AND RETAIL PHARMACIES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 18. HIV DRUGS MARKET FOR ONLINE PHARMACIES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 19. HIV DRUGS MARKET, BY REGION, 2022-2032 ($MILLION)
  • TABLE 20. NORTH AMERICA HIV DRUGS MARKET, BY MEDICATION CLASS, 2022-2032 ($MILLION)
  • TABLE 21. NORTH AMERICA HIV DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 22. NORTH AMERICA HIV DRUGS MARKET, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 23. U.S. HIV DRUGS MARKET, BY MEDICATION CLASS, 2022-2032 ($MILLION)
  • TABLE 24. U.S. HIV DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 25. CANADA HIV DRUGS MARKET, BY MEDICATION CLASS, 2022-2032 ($MILLION)
  • TABLE 26. CANADA HIV DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 27. MEXICO HIV DRUGS MARKET, BY MEDICATION CLASS, 2022-2032 ($MILLION)
  • TABLE 28. MEXICO HIV DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 29. EUROPE HIV DRUGS MARKET, BY MEDICATION CLASS, 2022-2032 ($MILLION)
  • TABLE 30. EUROPE HIV DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 31. EUROPE HIV DRUGS MARKET, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 32. GERMANY HIV DRUGS MARKET, BY MEDICATION CLASS, 2022-2032 ($MILLION)
  • TABLE 33. GERMANY HIV DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 34. FRANCE HIV DRUGS MARKET, BY MEDICATION CLASS, 2022-2032 ($MILLION)
  • TABLE 35. FRANCE HIV DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 36. UK HIV DRUGS MARKET, BY MEDICATION CLASS, 2022-2032 ($MILLION)
  • TABLE 37. UK HIV DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 38. ITALY HIV DRUGS MARKET, BY MEDICATION CLASS, 2022-2032 ($MILLION)
  • TABLE 39. ITALY HIV DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 40. SPAIN HIV DRUGS MARKET, BY MEDICATION CLASS, 2022-2032 ($MILLION)
  • TABLE 41. SPAIN HIV DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 42. REST OF EUROPE HIV DRUGS MARKET, BY MEDICATION CLASS, 2022-2032 ($MILLION)
  • TABLE 43. REST OF EUROPE HIV DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 44. ASIA-PACIFIC HIV DRUGS MARKET, BY MEDICATION CLASS, 2022-2032 ($MILLION)
  • TABLE 45. ASIA-PACIFIC HIV DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 46. ASIA-PACIFIC HIV DRUGS MARKET, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 47. JAPAN HIV DRUGS MARKET, BY MEDICATION CLASS, 2022-2032 ($MILLION)
  • TABLE 48. JAPAN HIV DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 49. CHINA HIV DRUGS MARKET, BY MEDICATION CLASS, 2022-2032 ($MILLION)
  • TABLE 50. CHINA HIV DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 51. AUSTRALIA HIV DRUGS MARKET, BY MEDICATION CLASS, 2022-2032 ($MILLION)
  • TABLE 52. AUSTRALIA HIV DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 53. INDIA HIV DRUGS MARKET, BY MEDICATION CLASS, 2022-2032 ($MILLION)
  • TABLE 54. INDIA HIV DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 55. SOUTH KOREA HIV DRUGS MARKET, BY MEDICATION CLASS, 2022-2032 ($MILLION)
  • TABLE 56. SOUTH KOREA HIV DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 57. REST OF ASIA-PACIFIC HIV DRUGS MARKET, BY MEDICATION CLASS, 2022-2032 ($MILLION)
  • TABLE 58. REST OF ASIA-PACIFIC HIV DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 59. LAMEA HIV DRUGS MARKET, BY MEDICATION CLASS, 2022-2032 ($MILLION)
  • TABLE 60. LAMEA HIV DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 61. LAMEA HIV DRUGS MARKET, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 62. BRAZIL HIV DRUGS MARKET, BY MEDICATION CLASS, 2022-2032 ($MILLION)
  • TABLE 63. BRAZIL HIV DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 64. SAUDI ARABIA HIV DRUGS MARKET, BY MEDICATION CLASS, 2022-2032 ($MILLION)
  • TABLE 65. SAUDI ARABIA HIV DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 66. SOUTH AFRICA HIV DRUGS MARKET, BY MEDICATION CLASS, 2022-2032 ($MILLION)
  • TABLE 67. SOUTH AFRICA HIV DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 68. REST OF LAMEA HIV DRUGS MARKET, BY MEDICATION CLASS, 2022-2032 ($MILLION)
  • TABLE 69. REST OF LAMEA HIV DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 70. ABBVIE INC.: KEY EXECUTIVES
  • TABLE 71. ABBVIE INC.: COMPANY SNAPSHOT
  • TABLE 72. ABBVIE INC.: PRODUCT SEGMENTS
  • TABLE 73. ABBVIE INC.: PRODUCT PORTFOLIO
  • TABLE 74. MERCK & CO., INC.: KEY EXECUTIVES
  • TABLE 75. MERCK & CO., INC.: COMPANY SNAPSHOT
  • TABLE 76. MERCK & CO., INC.: PRODUCT SEGMENTS
  • TABLE 77. MERCK & CO., INC.: PRODUCT PORTFOLIO
  • TABLE 78. MERCK & CO., INC.: KEY STRATERGIES
  • TABLE 79. BOEHRINGER INGELHEIM INTERNATIONAL GMBH: KEY EXECUTIVES
  • TABLE 80. BOEHRINGER INGELHEIM INTERNATIONAL GMBH: COMPANY SNAPSHOT
  • TABLE 81. BOEHRINGER INGELHEIM INTERNATIONAL GMBH: PRODUCT SEGMENTS
  • TABLE 82. BOEHRINGER INGELHEIM INTERNATIONAL GMBH: PRODUCT PORTFOLIO
  • TABLE 83. GILEAD SCIENCES, INC.: KEY EXECUTIVES
  • TABLE 84. GILEAD SCIENCES, INC.: COMPANY SNAPSHOT
  • TABLE 85. GILEAD SCIENCES, INC.: PRODUCT SEGMENTS
  • TABLE 86. GILEAD SCIENCES, INC.: PRODUCT PORTFOLIO
  • TABLE 87. GILEAD SCIENCES, INC.: KEY STRATERGIES
  • TABLE 88. GLAXOSMITHKLINE PLC: KEY EXECUTIVES
  • TABLE 89. GLAXOSMITHKLINE PLC: COMPANY SNAPSHOT
  • TABLE 90. GLAXOSMITHKLINE PLC: PRODUCT SEGMENTS
  • TABLE 91. GLAXOSMITHKLINE PLC: PRODUCT PORTFOLIO
  • TABLE 92. GLAXOSMITHKLINE PLC: KEY STRATERGIES
  • TABLE 93. JOHNSON & JOHNSON: KEY EXECUTIVES
  • TABLE 94. JOHNSON & JOHNSON: COMPANY SNAPSHOT
  • TABLE 95. JOHNSON & JOHNSON: PRODUCT SEGMENTS
  • TABLE 96. JOHNSON & JOHNSON: PRODUCT PORTFOLIO
  • TABLE 97. JOHNSON & JOHNSON: KEY STRATERGIES
  • TABLE 98. F. HOFFMANN-LA ROCHE LTD.: KEY EXECUTIVES
  • TABLE 99. F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT
  • TABLE 100. F. HOFFMANN-LA ROCHE LTD.: PRODUCT SEGMENTS
  • TABLE 101. F. HOFFMANN-LA ROCHE LTD.: PRODUCT PORTFOLIO
  • TABLE 102. TEVA PHARMACEUTICAL INDUSTRIES LTD.: KEY EXECUTIVES
  • TABLE 103. TEVA PHARMACEUTICAL INDUSTRIES LTD.: COMPANY SNAPSHOT
  • TABLE 104. TEVA PHARMACEUTICAL INDUSTRIES LTD.: PRODUCT SEGMENTS
  • TABLE 105. TEVA PHARMACEUTICAL INDUSTRIES LTD.: PRODUCT PORTFOLIO
  • TABLE 106. CIPLA LTD.: KEY EXECUTIVES
  • TABLE 107. CIPLA LTD.: COMPANY SNAPSHOT
  • TABLE 108. CIPLA LTD.: PRODUCT SEGMENTS
  • TABLE 109. CIPLA LTD.: PRODUCT PORTFOLIO
  • TABLE 110. BRISTOL-MYERS SQUIBB COMPANY: KEY EXECUTIVES
  • TABLE 111. BRISTOL-MYERS SQUIBB COMPANY: COMPANY SNAPSHOT
  • TABLE 112. BRISTOL-MYERS SQUIBB COMPANY: PRODUCT SEGMENTS
  • TABLE 113. BRISTOL-MYERS SQUIBB COMPANY: PRODUCT PORTFOLIO

LIST OF FIGURES

  • FIGURE 01. HIV DRUGS MARKET, 2022-2032
  • FIGURE 02. SEGMENTATION OF HIV DRUGS MARKET,2022-2032
  • FIGURE 03. TOP IMPACTING FACTORS IN HIV DRUGS MARKET (2022 TO 2032)
  • FIGURE 04. TOP INVESTMENT POCKETS IN HIV DRUGS MARKET (2023-2032)
  • FIGURE 05. LOW BARGAINING POWER OF SUPPLIERS
  • FIGURE 06. LOW THREAT OF NEW ENTRANTS
  • FIGURE 07. LOW THREAT OF SUBSTITUTES
  • FIGURE 08. LOW INTENSITY OF RIVALRY
  • FIGURE 09. LOW BARGAINING POWER OF BUYERS
  • FIGURE 10. GLOBAL HIV DRUGS MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES
  • FIGURE 11. HIV DRUGS MARKET, BY MEDICATION CLASS, 2022 AND 2032(%)
  • FIGURE 12. COMPARATIVE SHARE ANALYSIS OF HIV DRUGS MARKET FOR MULTI-CLASS COMBINATION DRUGS, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 13. COMPARATIVE SHARE ANALYSIS OF HIV DRUGS MARKET FOR NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS (NRTIS), BY COUNTRY 2022 AND 2032(%)
  • FIGURE 14. COMPARATIVE SHARE ANALYSIS OF HIV DRUGS MARKET FOR NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS (NNRTIS), BY COUNTRY 2022 AND 2032(%)
  • FIGURE 15. COMPARATIVE SHARE ANALYSIS OF HIV DRUGS MARKET FOR PROTEASE INHIBITORS (PIS), BY COUNTRY 2022 AND 2032(%)
  • FIGURE 16. COMPARATIVE SHARE ANALYSIS OF HIV DRUGS MARKET FOR ENTRY INHIBITORS, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 17. COMPARATIVE SHARE ANALYSIS OF HIV DRUGS MARKET FOR HIV INTEGRASE STRAND TRANSFER INHIBITORS, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 18. COMPARATIVE SHARE ANALYSIS OF HIV DRUGS MARKET FOR OTHERS, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 19. HIV DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022 AND 2032(%)
  • FIGURE 20. COMPARATIVE SHARE ANALYSIS OF HIV DRUGS MARKET FOR HOSPITAL PHARMACIES, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 21. COMPARATIVE SHARE ANALYSIS OF HIV DRUGS MARKET FOR DRUGS STORES AND RETAIL PHARMACIES, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 22. COMPARATIVE SHARE ANALYSIS OF HIV DRUGS MARKET FOR ONLINE PHARMACIES, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 23. HIV DRUGS MARKET BY REGION, 2022 AND 2032(%)
  • FIGURE 24. U.S. HIV DRUGS MARKET, 2022-2032 ($MILLION)
  • FIGURE 25. CANADA HIV DRUGS MARKET, 2022-2032 ($MILLION)
  • FIGURE 26. MEXICO HIV DRUGS MARKET, 2022-2032 ($MILLION)
  • FIGURE 27. GERMANY HIV DRUGS MARKET, 2022-2032 ($MILLION)
  • FIGURE 28. FRANCE HIV DRUGS MARKET, 2022-2032 ($MILLION)
  • FIGURE 29. UK HIV DRUGS MARKET, 2022-2032 ($MILLION)
  • FIGURE 30. ITALY HIV DRUGS MARKET, 2022-2032 ($MILLION)
  • FIGURE 31. SPAIN HIV DRUGS MARKET, 2022-2032 ($MILLION)
  • FIGURE 32. REST OF EUROPE HIV DRUGS MARKET, 2022-2032 ($MILLION)
  • FIGURE 33. JAPAN HIV DRUGS MARKET, 2022-2032 ($MILLION)
  • FIGURE 34. CHINA HIV DRUGS MARKET, 2022-2032 ($MILLION)
  • FIGURE 35. AUSTRALIA HIV DRUGS MARKET, 2022-2032 ($MILLION)
  • FIGURE 36. INDIA HIV DRUGS MARKET, 2022-2032 ($MILLION)
  • FIGURE 37. SOUTH KOREA HIV DRUGS MARKET, 2022-2032 ($MILLION)
  • FIGURE 38. REST OF ASIA-PACIFIC HIV DRUGS MARKET, 2022-2032 ($MILLION)
  • FIGURE 39. BRAZIL HIV DRUGS MARKET, 2022-2032 ($MILLION)
  • FIGURE 40. SAUDI ARABIA HIV DRUGS MARKET, 2022-2032 ($MILLION)
  • FIGURE 41. SOUTH AFRICA HIV DRUGS MARKET, 2022-2032 ($MILLION)
  • FIGURE 42. REST OF LAMEA HIV DRUGS MARKET, 2022-2032 ($MILLION)
  • FIGURE 43. PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 44. COMPETITIVE DASHBOARD
  • FIGURE 45. COMPETITIVE HEATMAP: HIV DRUGS MARKET
  • FIGURE 46. TOP PLAYER POSITIONING, 2022
  • FIGURE 47. ABBVIE INC.: NET REVENUE, 2020-2022 ($MILLION)
  • FIGURE 48. ABBVIE INC.: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 49. ABBVIE INC.: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 50. MERCK & CO., INC.: NET REVENUE, 2020-2022 ($MILLION)
  • FIGURE 51. MERCK & CO., INC.: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 52. MERCK & CO., INC.: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 53. BOEHRINGER INGELHEIM INTERNATIONAL GMBH: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 54. BOEHRINGER INGELHEIM INTERNATIONAL GMBH: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 55. BOEHRINGER INGELHEIM INTERNATIONAL GMBH: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 56. GILEAD SCIENCES, INC.: NET REVENUE, 2020-2022 ($MILLION)
  • FIGURE 57. GLAXOSMITHKLINE PLC: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 58. GLAXOSMITHKLINE PLC: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 59. GLAXOSMITHKLINE PLC: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 60. JOHNSON & JOHNSON: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 61. JOHNSON & JOHNSON: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 62. JOHNSON & JOHNSON: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 63. F. HOFFMANN-LA ROCHE LTD.: SALES REVENUE, 2020-2022 ($MILLION)
  • FIGURE 64. F. HOFFMANN-LA ROCHE LTD.: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 65. TEVA PHARMACEUTICAL INDUSTRIES LTD.: NET REVENUE, 2020-2022 ($MILLION)
  • FIGURE 66. TEVA PHARMACEUTICAL INDUSTRIES LTD.: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 67. CIPLA LTD.: SALES REVENUE, 2020-2022 ($MILLION)
  • FIGURE 68. CIPLA LTD.: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 69. CIPLA LTD.: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 70. BRISTOL-MYERS SQUIBB COMPANY: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 71. BRISTOL-MYERS SQUIBB COMPANY: REVENUE SHARE BY REGION, 2022 (%)